• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

趋化因子受体(CXCR4)拮抗剂T22([酪氨酸(5,12),赖氨酸7] - 多聚半胱氨酸II)的药效团鉴定,该拮抗剂可特异性阻断T细胞系嗜性HIV-1感染。

Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.

作者信息

Tamamura H, Imai M, Ishihara T, Masuda M, Funakoshi H, Oyake H, Murakami T, Arakaki R, Nakashima H, Otaka A, Ibuka T, Waki M, Matsumoto A, Yamamoto N, Fujii N

机构信息

Graduate School of Pharmaceutical Sciences, Kyoto University, Japan.

出版信息

Bioorg Med Chem. 1998 Jul;6(7):1033-41. doi: 10.1016/s0968-0896(98)00061-3.

DOI:10.1016/s0968-0896(98)00061-3
PMID:9730240
Abstract

We have previously found that T22 ([Tyr(5,12), Lys7]-polyphemusin II) has strong anti-human immunodeficiency virus (HIV) activity, and that T22 inhibits T cell-line-tropic HIV-1 infection mediated by CXCR4/fusin. T22 is an 18-residue peptide amide, which takes an antiparallel beta-sheet structure that is maintained by two disulfide bridges. Structure-activity relationship (SAR) studies on T22 have disclosed the contributions of each region of T22 to activity or cytotoxicity, and have provided the following useful information to develop new CXCR4 antagonists: The number of Arg residues in the N-terminal and C-terminal regions of T22 is closely related to anti-HIV activity. Addition of a variety of functional groups at the N-terminal end results in increases in activity. Disulfide rings, especially the major disulfide loop, are indispensable for anti-HIV activity and maintenance of the beta-sheet structure. Trp3 can be replaced by other aromatic residues (Tyr, Phe and L-2-naphthylalanine). Between two repeats of Tyr-Arg-Lys, which are a characteristic structure in T22, Tyr-Arg-Lys in the N-terminal portion is more closely associated with anti-HIV activity and maintenance of the beta-sheet structure. A positive charge in the side chain at the (i + 1) position of the beta-turn region is necessary for strong activity. Through these studies, we have found several compounds having higher selectivity indexes (50% cytotoxic concentration/50% effective concentration) than that of T22.

摘要

我们之前发现,T22([酪氨酸(5,12),赖氨酸7]-海胆精蛋白II)具有很强的抗人类免疫缺陷病毒(HIV)活性,并且T22可抑制由CXCR4/融合素介导的T细胞系嗜性HIV-1感染。T22是一种由18个氨基酸残基组成的肽酰胺,呈反平行β-折叠结构,由两个二硫键维持。对T22的构效关系(SAR)研究揭示了T22各个区域对活性或细胞毒性的贡献,并为开发新的CXCR4拮抗剂提供了以下有用信息:T22 N端和C端区域的精氨酸残基数量与抗HIV活性密切相关。在N端添加各种官能团会导致活性增加。二硫键环,尤其是主要的二硫键环,对于抗HIV活性和β-折叠结构的维持是不可或缺的。色氨酸3可以被其他芳香族残基(酪氨酸、苯丙氨酸和L-2-萘丙氨酸)取代。在T22的特征结构酪氨酸-精氨酸-赖氨酸的两个重复序列之间,N端部分的酪氨酸-精氨酸-赖氨酸与抗HIV活性和β-折叠结构的维持更密切相关。β-转角区域(i + 1)位侧链上的正电荷对于强活性是必需的。通过这些研究,我们发现了几种选择性指数(50%细胞毒性浓度/50%有效浓度)比T22更高的化合物。

相似文献

1
Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.趋化因子受体(CXCR4)拮抗剂T22([酪氨酸(5,12),赖氨酸7] - 多聚半胱氨酸II)的药效团鉴定,该拮抗剂可特异性阻断T细胞系嗜性HIV-1感染。
Bioorg Med Chem. 1998 Jul;6(7):1033-41. doi: 10.1016/s0968-0896(98)00061-3.
2
Structure-activity relationships of an anti-HIV peptide, T22.抗HIV肽T22的构效关系
Biochem Biophys Res Commun. 1994 Dec 30;205(3):1729-35. doi: 10.1006/bbrc.1994.2868.
3
Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure.一种HIV细胞融合抑制剂T22([酪氨酸5,12,赖氨酸7] - 海胆精蛋白II)的缩微化,同时保持抗HIV活性和溶液结构。
Bioorg Med Chem. 1998 Apr;6(4):473-9. doi: 10.1016/s0968-0896(97)10055-4.
4
Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.一种特异性CXCR4抑制剂T140的药效团鉴定,促成了具有非常高选择性指数的有效抗HIV药物的研发。
Bioorg Med Chem Lett. 2000 Dec 4;10(23):2633-7. doi: 10.1016/s0960-894x(00)00535-7.
5
A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection.一种可阻断T细胞系嗜性HIV-1感染的小分子CXCR4抑制剂。
J Exp Med. 1997 Oct 20;186(8):1389-93. doi: 10.1084/jem.186.8.1389.
6
A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.一种针对趋化因子受体CXCR4的低分子量抑制剂:强效抗HIV肽T140。
Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82. doi: 10.1006/bbrc.1998.9871.
7
Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.CXCR4拮抗剂T22对1型人类免疫缺陷病毒感染的抑制机制
J Virol. 1999 Sep;73(9):7489-96. doi: 10.1128/JVI.73.9.7489-7496.1999.
8
Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.鲎素类似物对CXCR4的结合能力增强,导致抗HIV活性以及对CXCR4介导的HIV进入的抑制活性显著增加。
AIDS Res Hum Retroviruses. 1999 Mar 20;15(5):419-27. doi: 10.1089/088922299311169.
9
Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II).一种HIV细胞融合抑制剂T22([酪氨酸5,12,赖氨酸7] - 海螯虾抗菌肽II)的高效低细胞毒性类似物
Bioorg Med Chem. 1998 Feb;6(2):231-8. doi: 10.1016/s0968-0896(97)10037-2.
10
An anti-HIV peptide, T22, forms a highly active complex with Zn(II).一种抗HIV肽T22与锌(II)形成一种高活性复合物。
Biochem Biophys Res Commun. 1996 Dec 13;229(2):648-52. doi: 10.1006/bbrc.1996.1858.

引用本文的文献

1
Targeting the chemokine receptor CXCR4 for cancer therapies.以趋化因子受体CXCR4为靶点进行癌症治疗。
Biomark Res. 2025 May 1;13(1):68. doi: 10.1186/s40364-025-00778-y.
2
The Diphtheria Toxin Translocation Domain Impairs Receptor Selectivity in Cancer Cell-Targeted Protein Nanoparticles.白喉毒素转位结构域损害癌细胞靶向蛋白纳米颗粒中的受体选择性。
Pharmaceutics. 2022 Nov 29;14(12):2644. doi: 10.3390/pharmaceutics14122644.
3
An In Silico Methodology That Facilitates Decision Making in the Engineering of Nanoscale Protein Materials.
一种有助于纳米尺度蛋白质材料工程设计中决策制定的计算方法。
Int J Mol Sci. 2022 Apr 29;23(9):4958. doi: 10.3390/ijms23094958.
4
The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies.多组氨酸标签H6介导崩解性、蛋白质释放型包涵体的结构和功能特性。
Pharmaceutics. 2022 Mar 10;14(3):602. doi: 10.3390/pharmaceutics14030602.
5
Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials.肿瘤靶向蛋白-MMAE纳米共轭物从可植入混合材料中的长时间释放
Pharmaceutics. 2022 Jan 14;14(1):192. doi: 10.3390/pharmaceutics14010192.
6
Antibacterial Activity of T22, a Specific Peptidic Ligand of the Tumoral Marker CXCR4.肿瘤标志物CXCR4的特异性肽配体T22的抗菌活性
Pharmaceutics. 2021 Nov 13;13(11):1922. doi: 10.3390/pharmaceutics13111922.
7
Ion-dependent slow protein release from disintegrating micro-granules.离子依赖性崩解微丸的缓慢蛋白释放。
Drug Deliv. 2021 Dec;28(1):2383-2391. doi: 10.1080/10717544.2021.1998249.
8
Biofabrication of functional protein nanoparticles through simple His-tag engineering.通过简单的组氨酸标签工程实现功能性蛋白质纳米颗粒的生物制造。
ACS Sustain Chem Eng. 2021 Sep 13;9(36):12341-12354. doi: 10.1021/acssuschemeng.1c04256. Epub 2021 Aug 30.
9
Self-Assembled Nanobodies as Selectively Targeted, Nanostructured, and Multivalent Materials.自组装纳米抗体作为选择性靶向、纳米结构和多价的材料。
ACS Appl Mater Interfaces. 2021 Jun 30;13(25):29406-29415. doi: 10.1021/acsami.1c08092. Epub 2021 Jun 15.
10
Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands.基于微量滴定板的抗体竞争分析测定 CXCR4 配体的结合亲和力和血浆/血液稳定性。
Sci Rep. 2020 Sep 29;10(1):16036. doi: 10.1038/s41598-020-73012-4.